Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 4
2013 4
2014 2
2015 1
2016 2
2017 3
2018 8
2019 3
2020 4
2021 6
2022 2
2023 13
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial.
Dizman N, Meza L, Bergerot P, Alcantara M, Dorff T, Lyou Y, Frankel P, Cui Y, Mira V, Llamas M, Hsu J, Zengin Z, Salgia N, Salgia S, Malhotra J, Chawla N, Chehrazi-Raffle A, Muddasani R, Gillece J, Reining L, Trent J, Takahashi M, Oka K, Higashi S, Kortylewski M, Highlander SK, Pal SK. Dizman N, et al. Among authors: hsu j. Nat Med. 2022 Apr;28(4):704-712. doi: 10.1038/s41591-022-01694-6. Epub 2022 Feb 28. Nat Med. 2022. PMID: 35228755 Free PMC article. Clinical Trial.
Adjuvant treatment in renal cell carcinoma.
Dizman N, Adashek JJ, Hsu J, Bergerot PG, Bergerot CD, Pal SK. Dizman N, et al. Among authors: hsu j. Clin Adv Hematol Oncol. 2018 Aug;16(8):555-563. Clin Adv Hematol Oncol. 2018. PMID: 30148828 Review.
Association Between Time-of-Day of Immune Checkpoint Blockade Administration and Outcomes in Metastatic Renal Cell Carcinoma.
Dizman N, Govindarajan A, Zengin ZB, Meza L, Tripathi N, Sayegh N, Castro DV, Chan EH, Lee KO, Prajapati S, Feng M, Loo V, Pace M, O'Brien S, Bailey E, Barragan-Carrillo R, Chehrazi-Raffle A, Hsu J, Li X, Agarwal N, Pal SK. Dizman N, et al. Among authors: hsu j. Clin Genitourin Cancer. 2023 Oct;21(5):530-536. doi: 10.1016/j.clgc.2023.06.004. Epub 2023 Jun 25. Clin Genitourin Cancer. 2023. PMID: 37495481
Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors.
Chawla NS, Sayegh N, Tripathi N, Govindarajan A, Zengin ZB, Phillip EJ, Dizman N, Meza L, Muddasani R, Chehrazi-Raffle A, Malhotra J, Hsu J, Agarwal N, Pal SK, Tripathi A. Chawla NS, et al. Among authors: hsu j. Clin Genitourin Cancer. 2023 Feb;21(1):69-75. doi: 10.1016/j.clgc.2022.11.007. Epub 2022 Nov 18. Clin Genitourin Cancer. 2023. PMID: 36509613
Patients' Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19.
Bergerot CD, Malhotra J, Bergerot P, Philip EJ, Castro DV, Hsu J, Mota ACA, Cardoso de Azeredo A, Neto JNM, Hutson T, Grünwald V, Bex A, Psutka SP, Rini B, Plimack ER, Master V, Albiges L, Choueiri TK, Pal S, Powles T. Bergerot CD, et al. Among authors: hsu j. Oncologist. 2023 Jun 2;28(6):494-500. doi: 10.1093/oncolo/oyad028. Oncologist. 2023. PMID: 36917626 Free PMC article.
Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy.
Alcantara MB, Tang WS, Wang D, Kaniowski D, Kang E, Dizman N, Chehrazi-Raffle A, Meza L, Zengin Z, Hall J, Hsu J, Egelston C, Moreira D, Horsager A, Pal SK, Kortylewski M. Alcantara MB, et al. Among authors: hsu j. Front Immunol. 2024 Jan 8;14:1274781. doi: 10.3389/fimmu.2023.1274781. eCollection 2023. Front Immunol. 2024. PMID: 38259453 Free PMC article.
Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma.
Chehrazi-Raffle A, Muddasani R, Dizman N, Hsu J, Meza L, Zengin ZB, Malhotra J, Chawla N, Dorff T, Contente-Cuomo T, Dinwiddie D, McDonald BR, McDaniel T, Trent JM, Baehner FL, Murtaza M, Pal SK. Chehrazi-Raffle A, et al. Among authors: hsu j. JCO Precis Oncol. 2023 Apr;7:e2200543. doi: 10.1200/PO.22.00543. JCO Precis Oncol. 2023. PMID: 37027813 Free PMC article.
Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis.
Meza L, Zengin Z, Salgia S, Malhotra J, Karczewska E, Dorff T, Tripathi A, Ely J, Kelley E, Mead H, Hsu J, Dizman N, Salgia N, Chawla N, Chehrazi-Raffle A, Muddasani R, Govindarajan A, Rock A, Liu S, Salgia R, Trent J, Altin J, Pal SK. Meza L, et al. Among authors: hsu j. Oncologist. 2023 Sep 7;28(9):e748-e755. doi: 10.1093/oncolo/oyad067. Oncologist. 2023. PMID: 36971500 Free PMC article.
Perceptions of COVID-19 Vaccination in Patients with Genitourinary Cancers: A Survey Study.
Castro DV, Zengin ZB, Malhotra J, Bergerot CD, Meza L, Dizman N, Govindarajan A, Hsu J, Chehrazi-Raffle A, Chawla N, Mercier BD, Chen SW, Feng M, Prajapati S, Lee KO, Philip EJ, Dorff TB, Lyou Y, Pal SK. Castro DV, et al. Among authors: hsu j. Cancer Invest. 2023 Jan;41(1):70-76. doi: 10.1080/07357907.2022.2136683. Epub 2023 Jan 5. Cancer Invest. 2023. PMID: 36239609
43 results